Clinical Trial

A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

Study acronym: SPOTLIGHT
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-05-21
Trial Details
NCT Number NCT07456774
Lead Sponsor Novo Nordisk A/S
Conditions Type 2 Diabetes
Enrollment 100,000 participants
Start Date 2026-02-13
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-20